HK1073606A1 - Use of edg receptor binding agents in cancer edg - Google Patents

Use of edg receptor binding agents in cancer edg

Info

Publication number
HK1073606A1
HK1073606A1 HK05106241.9A HK05106241A HK1073606A1 HK 1073606 A1 HK1073606 A1 HK 1073606A1 HK 05106241 A HK05106241 A HK 05106241A HK 1073606 A1 HK1073606 A1 HK 1073606A1
Authority
HK
Hong Kong
Prior art keywords
edg
cancer
receptor binding
binding agents
sphingosine
Prior art date
Application number
HK05106241.9A
Other languages
English (en)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth Richard La
Peter T Lassota
Diana Mechtcheriakova
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1073606A1 publication Critical patent/HK1073606A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK05106241.9A 2002-05-16 2005-07-22 Use of edg receptor binding agents in cancer edg HK1073606A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
PCT/EP2003/005125 WO2003097028A1 (fr) 2002-05-16 2003-05-15 Utilisation d'agents de liaison du recepteur edg dans le cancer

Publications (1)

Publication Number Publication Date
HK1073606A1 true HK1073606A1 (en) 2005-10-14

Family

ID=29554311

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05106241.9A HK1073606A1 (en) 2002-05-16 2005-07-22 Use of edg receptor binding agents in cancer edg
HK09104529.3A HK1126127A1 (en) 2002-05-16 2009-05-18 Use of edg receptor binding agents in cancer edg

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09104529.3A HK1126127A1 (en) 2002-05-16 2009-05-18 Use of edg receptor binding agents in cancer edg

Country Status (23)

Country Link
US (2) US20090209495A1 (fr)
EP (3) EP1505959B1 (fr)
JP (3) JP5227492B2 (fr)
KR (1) KR20120125398A (fr)
CN (1) CN1652757B (fr)
AT (1) ATE412408T1 (fr)
AU (1) AU2003240655B2 (fr)
BR (1) BR0311173A (fr)
CA (1) CA2483594C (fr)
CY (1) CY1108719T1 (fr)
DE (1) DE60324416D1 (fr)
DK (1) DK1505959T3 (fr)
ES (1) ES2316758T3 (fr)
HK (2) HK1073606A1 (fr)
IL (3) IL164838A (fr)
MX (1) MXPA04011384A (fr)
NO (2) NO334074B1 (fr)
NZ (2) NZ560662A (fr)
PL (1) PL372103A1 (fr)
PT (1) PT1505959E (fr)
SI (1) SI1505959T1 (fr)
WO (1) WO2003097028A1 (fr)
ZA (1) ZA200408575B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
AU2003202495B2 (en) 2002-01-11 2006-07-20 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
CA2488425A1 (fr) 2002-06-07 2003-12-18 Es Cell International Pte Ltd Procedes de regulation de la differenciation des cellules souches
EP2172472B1 (fr) * 2003-02-18 2012-12-26 Kyorin Pharmaceutical Co., Ltd. Dérivé d'acide aminophosphonique et son sel d'addition et modulateur du récepteur S1P
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
AU2005272619A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
PT1812797E (pt) * 2004-10-28 2013-05-21 Lpath Inc Composições e métodos para o tratamento e prevenção de doenças hiperproliferativas
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
CN101415691B (zh) 2006-02-03 2011-12-14 大正制药株式会社 ***衍生物
JP5218737B2 (ja) 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−１−リン酸結合阻害物質
KR20080108156A (ko) * 2006-04-06 2008-12-11 노파르티스 아게 유기 화합물의 조합물
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
CA2667706A1 (fr) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions et procedes pour traiter des maladies et des troubles oculaires
DK2177512T3 (da) 2007-08-01 2012-06-18 Taisho Pharmaceutical Co Ltd S1P1-bindingshæmmer
EP2177521A1 (fr) 2008-10-14 2010-04-21 Almirall, S.A. Nouveaux dérivés de 2-amidothiadiazole
ES2643161T3 (es) * 2008-11-11 2017-11-21 Novartis Ag Formas cristalinas de HCL de fingolimod
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
ES2760607T3 (es) 2008-12-22 2020-05-14 Novartis Ag Régimen de dosificación para un agonista del receptor s1p
SI2379069T1 (sl) 2008-12-22 2015-07-31 Novartis Ag Režim odmerjanja agonista receptorja S1P
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
EP2456752A2 (fr) 2009-07-24 2012-05-30 ratiopharm GmbH Procédé pour la production de sels de fingolimod
EP2305660A1 (fr) 2009-09-25 2011-04-06 Almirall, S.A. Nouveaux dérivés de thiadiazole
SG10201406168RA (en) 2009-09-29 2014-11-27 Novartis Ag Dosage regimen of an s1p receptor modulator
EP2343287A1 (fr) 2009-12-10 2011-07-13 Almirall, S.A. Nouveaux dérivés de 2-aminothiadiazole
EP2366702A1 (fr) 2010-03-18 2011-09-21 Almirall, S.A. Nouveaux dérivés d'oxadiazole
EP2390252A1 (fr) 2010-05-19 2011-11-30 Almirall, S.A. Nouveaux dérivés de pyrazole
WO2012071524A1 (fr) 2010-11-24 2012-05-31 Ratiopharm Gmbh Sels d'arylsulfonates de fingolimod et leurs procédés de préparation
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
CN106278999B (zh) 2011-02-07 2019-10-25 比奥根Ma公司 S1p调节剂
SG11201401065RA (en) 2011-10-21 2014-09-26 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
AU2012354695B2 (en) * 2011-12-23 2016-11-03 Meiji Seika Pharma Co., Ltd. Novel S1P receptor modulator
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2879673B1 (fr) 2012-08-06 2018-07-25 Biogen MA Inc. Dérivés de la naphthaline substitué 1,5,6 en tant que modulateurs du récepteur sphingosine 1 phosphate (S1P) et/ou autotaxin (ATX) pour le traitement de maladies d'inflammation et d'auto-immunité
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
WO2014081756A1 (fr) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. Agents de modulation de s1p et/ou atx
WO2014120764A1 (fr) 2013-01-29 2014-08-07 Biogen Idec Ma Inc. Agents modulateurs de s1p
TW201446768A (zh) 2013-03-15 2014-12-16 Biogen Idec Inc S1p及/或atx調節劑
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 ***上调内皮***保护分子鞘氨醇1-磷酸的应用
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3443986A1 (fr) 2017-08-17 2019-02-20 AC BioScience Amélioration de l'efficacité d'une chimiothérapie par la sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DE69233739D1 (de) 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
EP0817775B1 (fr) 1995-03-30 2001-09-12 Pfizer Inc. Derives de quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
BR9709959A (pt) 1996-06-24 2000-05-09 Pfizer Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (fr) 1996-09-13 1998-03-19 Sugen, Inc. Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1998045249A1 (fr) * 1997-04-04 1998-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6423508B1 (en) * 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
JP4516690B2 (ja) 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CA2355976C (fr) 1998-12-22 2012-07-17 Genentech, Inc. Antagonistes du facteur de croissance endotheliale et leurs utilisations
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
JP4837864B2 (ja) * 2000-02-09 2011-12-14 ノバルティス アーゲー 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
WO2002045717A1 (fr) * 2000-12-06 2002-06-13 Tularik Inc. Polytherapie a base de lometrexol
DE60208355T2 (de) 2001-03-26 2006-07-27 Novartis Ag 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CN1329372C (zh) * 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤

Also Published As

Publication number Publication date
IL229559A0 (en) 2014-01-30
IL164838A (en) 2013-12-31
CA2483594A1 (fr) 2003-11-27
EP1955696A3 (fr) 2011-05-25
JP2010100637A (ja) 2010-05-06
BR0311173A (pt) 2005-03-15
SI1505959T1 (sl) 2009-04-30
US20140303257A1 (en) 2014-10-09
NO20130106L (no) 2004-12-03
ZA200408575B (en) 2005-07-27
CN1652757A (zh) 2005-08-10
WO2003097028A1 (fr) 2003-11-27
ES2316758T3 (es) 2009-04-16
JP2005529921A (ja) 2005-10-06
IL164838A0 (en) 2005-12-18
PT1505959E (pt) 2009-02-05
HK1126127A1 (en) 2009-08-28
DE60324416D1 (de) 2008-12-11
CA2483594C (fr) 2011-02-15
EP1944026A3 (fr) 2011-06-01
KR20120125398A (ko) 2012-11-14
NZ536513A (en) 2007-10-26
EP1505959A1 (fr) 2005-02-16
EP1955696B1 (fr) 2014-05-28
JP2013136584A (ja) 2013-07-11
EP1505959B1 (fr) 2008-10-29
EP1944026B1 (fr) 2013-06-26
DK1505959T3 (da) 2009-02-23
CN1652757B (zh) 2012-02-08
JP5227492B2 (ja) 2013-07-03
EP1955696A2 (fr) 2008-08-13
NO20045312L (no) 2004-12-03
NZ560662A (en) 2009-09-25
US20090209495A1 (en) 2009-08-20
IL229550A0 (en) 2014-01-30
EP1944026A2 (fr) 2008-07-16
PL372103A1 (en) 2005-07-11
AU2003240655B2 (en) 2007-09-06
AU2003240655A1 (en) 2003-12-02
CY1108719T1 (el) 2014-04-09
ATE412408T1 (de) 2008-11-15
NO334074B1 (no) 2013-12-02
MXPA04011384A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
IL229550A0 (en) Use of substances that bind to the edg receptor in cancer
EP1487436A4 (fr) Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
TWI372628B (en) Methods of modulating cytokine activity; related reagents
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
IL139641A0 (en) Quinazolines for treating brain tumor
EP1226823A3 (fr) Méthode de traitement de certains cancers avec un agoniste/antagoniste des estrogènes
AU2003264068A8 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
AU2001227966A1 (en) Methods for treating tumors
YU38102A (sh) Derivati arilamina i njihova primena kao antitelomerazno sredstvo
GB2359314B (en) Technique for treating wells
AP2004003070A0 (en) The method of treating cancer.
SI1350521T1 (sl) Imunoterapevtske kombinacije za zdravljenje tumorjev
GB2348899B (en) Surface treatment for tungsten carbide insert
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
WO2004031775A3 (fr) Methode de traitement ou de prevention de la metastase de cancers colorectaux
AU2228299A (en) Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
GB2379444A9 (en) Assay for cancer of the prostate
AU2001247560A8 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
HK1023990A1 (en) Surface treating agent for metals containing polyoxyethylene alkylphenol ether derivatives
GB9905113D0 (en) Chisel and plane-iron renovating and honing guide
GB9903035D0 (en) Treating cancer
WO2004111262A8 (fr) Procede d'identification d'un agent chimiotherapeutique selectif
ZA200307471B (en) Carbamate compounds for use in preventing or treating bipolar disorder.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150515